Reviewing Adverse Drug Event Reporting Between Randomized Clinical Trial Data and Real World Post Market Data for Sorafenib and Sunitinib
May 1, 2018, 00:00
10.1016/j.jval.2018.04.081
https://www.valueinhealthjournal.com/article/S1098-3015(18)30381-4/fulltext
Title :
Reviewing Adverse Drug Event Reporting Between Randomized Clinical Trial Data and Real World Post Market Data for Sorafenib and Sunitinib
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30381-4&doi=10.1016/j.jval.2018.04.081
First page :
Section Title :
Open access? :
No
Section Order :
244